Outcomes of Patients With MDS After Secondary Failure of Hypomethylating Drugs

Mojtaba Akhtari

Outcomes of Patients With MDS After Secondary Failure of Hypomethylating Drugs

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Default journal
State	Published - Dec 3 2011

Disciplines

Oncology
Internal Medicine
Medicine and Health Sciences

OpenUrl availability

Full text

Cite this

@article{f06dcbc84abb4786bab99e66c24e8ef3,

title = "Outcomes of Patients With MDS After Secondary Failure of Hypomethylating Drugs",

author = "Mojtaba Akhtari",

note = "Hypomethylating drugs azacitidine and decitabine have shown significant clinical activity with hematologic and cytogenetic responses in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML); and they are now the standard of care for patients with MDS and CMML.",

year = "2011",

month = dec,

day = "3",

language = "American English",

journal = "Default journal",

}

TY - JOUR

T1 - Outcomes of Patients With MDS After Secondary Failure of Hypomethylating Drugs

AU - Akhtari, Mojtaba

N1 - Hypomethylating drugs azacitidine and decitabine have shown significant clinical activity with hematologic and cytogenetic responses in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML); and they are now the standard of care for patients with MDS and CMML.

PY - 2011/12/3

Y1 - 2011/12/3

UR - https://www.cancernetwork.com/hematologic-malignancies/outcomes-patients-mds-after-secondary-failure-hypomethylating-drugs

M3 - Article

JO - Default journal

JF - Default journal

ER -

Outcomes of Patients With MDS After Secondary Failure of Hypomethylating Drugs

Disciplines

OpenUrl availability

Other files and links

Cite this